300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
InsurTech
Platforms
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Email
Photography
Payments
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
B2B
Facebook
Blockchain
Social Network
Video Games
Big Data
Medical Device
Mobile
Wellness
Automotive
Sports
Education
Legal
Hospitality
Biotechnology
eSports
Consumer
Construction
Renewable Energy
Software
Crowdfunding
Venture Capital
Fashion
Theatre
Social
Medical
Beauty
Recruiting
Infrastructure
Web3
Cannabis
Mobile Apps
LGBT
Life Science
Celebrity
Climate
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
Food and Beverage
Digital Media
FinTech
Finance
Publishing
Financial Services
Social Media
Franchise
Mobile Advertising
Android
Non Profit
Internet
Sustainability
Hardware
Biotech
Impact
Enterprise
Proptech
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
South Korea
Croatia
Burkina Faso
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Gibraltar
Oceania
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Mexico
Norway
Tajikistan
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Romania
Pakistan
Puerto Rico
Oman
Poland
Cameroon
Andorra
Guernsey
Sudan
Colombia
Armenia
China
Costa Rica
Kenya
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Morocco
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
Japan
Ireland
Canada
South Africa
United Kingdom
France
Georgia
Ghana
Denmark
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
United States
India
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Angola
Europe
Cyprus
Qatar
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Bahamas
Ecuador
Bolivia
Algeria
Faroe Islands
Belize
Estonia
Finland
Italy
Belarus
Hungary
Jersey
Bahrain
Grenada
Israel
Iceland
Liechtenstein
Cambodia
Honduras
Lithuania
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
TCD Capital, VC Fund

TCD Capital

VC Fund

Uccle, Belgium

TCD Capital is a VC fund in Uccle focused on Biotechnology and Health Care. TheClubDeal is an investment holding and fund manager co-investing into SME’s and real estate projects. It provides facilitation of governance between non-executive shareholders and entrepreneurs. Its governance structure, including its charter of avoidance of conflict of interests, is therefore paramount to the adequate management of the Company.At TheClubDeal, we connect Investors and Entrepreneurs around promising investment opportunities. For each of these, we will invest ourselves and co-invest with a selected number of investors. We add value by processing strong applied governance principles, when selecting and managing our investments, and by gathering the necessary skills to successfully grow the businesses and real-estate projects we co-invest in. TheClubDeal is launching their second fund, a 50M € PRIVAK/PRICAF in H1 2021 with the mandate to invest in Belgian scale-ups in three sectors: Smart Living, Tech and Life Sciences.

Total investments:
18
Last investment:
Lead investor:
33%

Last updated:

Industries TCD Capital invests in

BiotechnologyHealth CareMedical DeviceClinical TrialsInformation Technology

Stages TCD Capital invests in

Series ASeries BVenture - Series UnknownSeedSeries C

Countries TCD Capital invests in

BelgiumFrance

Round sizes

Series A $2.1M–$7.7MSeries B $13M–$18MVenture - Series Unknown $5.5M–$6.5M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$2.1M–$7.7M
Series B
$13M–$18M
Venture - Series Unknown
$5.5M–$6.5M

Investment Focus

Industry

  • Biotechnology 4 (22%)
  • Health Care 3 (17%)
  • Medical Device 2 (11%)
  • Clinical Trials 2 (11%)
  • Information Technology 2 (11%)
See all 31 industries →

Stage

  • Series A 9 (50%)
  • Series B 2 (11%)
  • Venture - Series Unknown 2 (11%)
  • Seed 1 (6%)
  • Series C 1 (6%)
See all 6 stages →

Country

  • Belgium 10 (56%)
  • France 4 (22%)

Team

NameTitleInvestmentsLinksEmail
Jean-Louis Dubrule Executive partner and Board Member
Executive partner and Board Member Total investments: 0
Find email
Jean-Marc Legrand Founder & Managing Director
Founder & Managing Director Total investments: 0
Find email
Xavier de Villepin
Xavier de Villepin Business & Investment Manager
Business & Investment Manager Total investments: 0
Find email
Edouard de Becker Remy
Edouard de Becker Remy Investment Analyst
Investment Analyst Total investments: 0
Find email
Frederic Convent Senior Investment Manager
Senior Investment Manager Total investments: 0
Find email
See all 7 team members →

Investments

CompanyDescriptionRoundLinks
Vaxinano Vaxinano
Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder. $6.5M / Venture - Series Unknown / Oct 29, 2024
Clouds of care Clouds of care
CLOUDS OF CARE aids HealthTech firms from algorithm validation to medical device software, focusing on regulatory compliance. $5.5M / Venture - Series Unknown / Sep 04, 2024
Inpulse Inpulse
Inpulse is an automated supply management platform for restaurateurs. $7.7M / Series A / Apr 19, 2023
Univercells Univercells
Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. $43.3M / Series D / Oct 17, 2022
FLYX.cloud FLYX.cloud
FLYX.cloud enables retail chains to maximise value from each customer in multiple industries (such as Food, Grocery and Fuel) and in an omni-channel sales model. $2.1M / Series A / Jun 01, 2022
Smartflats Smartflats
Smartflats constructs and distributes a range of flats for its clients.The company provides its users with an online platform to make bookings for their stay. It enables them to make food orders and obtain transfer services. Furthermore, it provides wireless internet, TVs, coffee makers, irons, and hairdryers.Smartflats was founded in 2012 byTarik Hennen and Alexandre Szmaj. $4.9M / Series A / Oct 01, 2021
Sortlist Sortlist
Because finding the right partner in the fast-growing digital environment is a hard task, we have built an online multi-criteria searching tool strongly linked to professional networks and peer-to-peer recommendations. Sortlist helps marketing managers find their partners in minutes and let them focus on building communication and marketingsuccess.Start your search now on www.sortlist.com $13M / Series B / Sep 15, 2021
Univercells Univercells
Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. $24.5M / Series C / Dec 17, 2020
Univercells Univercells
Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. Series C / Aug 31, 2020
Yust Group Yust Group
Co-Living, Smart Living Seed / Apr 30, 2019
See all 18 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
InsurTech
Platforms
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Email
Photography
Payments
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
B2B
Facebook
Blockchain
Social Network
Video Games
Big Data
Medical Device
Mobile
Wellness
Automotive
Sports
Education
Legal
Hospitality
Biotechnology
eSports
Consumer
Construction
Renewable Energy
Software
Crowdfunding
Venture Capital
Fashion
Theatre
Social
Medical
Beauty
Recruiting
Infrastructure
Web3
Cannabis
Mobile Apps
LGBT
Life Science
Celebrity
Climate
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
Food and Beverage
Digital Media
FinTech
Finance
Publishing
Financial Services
Social Media
Franchise
Mobile Advertising
Android
Non Profit
Internet
Sustainability
Hardware
Biotech
Impact
Enterprise
Proptech
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
South Korea
Croatia
Burkina Faso
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Gibraltar
Oceania
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Mexico
Norway
Tajikistan
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Romania
Pakistan
Puerto Rico
Oman
Poland
Cameroon
Andorra
Guernsey
Sudan
Colombia
Armenia
China
Costa Rica
Kenya
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Morocco
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
Japan
Ireland
Canada
South Africa
United Kingdom
France
Georgia
Ghana
Denmark
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
United States
India
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Angola
Europe
Cyprus
Qatar
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Bahamas
Ecuador
Bolivia
Algeria
Faroe Islands
Belize
Estonia
Finland
Italy
Belarus
Hungary
Jersey
Bahrain
Grenada
Israel
Iceland
Liechtenstein
Cambodia
Honduras
Lithuania
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does TCD Capital invest in?

TCD Capital invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is TCD Capital's check size?

TCD Capital typically joins rounds of $2.1M–$7.7M at Series A, $13M–$18M at Series B and $5.5M–$6.5M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TCD Capital participates in.

How do I contact TCD Capital?

Public channels for TCD Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at TCD Capital?

The team at TCD Capital includes Jean-Louis Dubrule (Executive partner and Board Member), Jean-Marc Legrand (Founder & Managing Director) and Xavier de Villepin (Business & Investment Manager), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
TCD Capital TCD Capital Find emails